Technology Centre of New Jersey

Available for Lease - View the Tech Centre Interactive Flash Brochure

Novo Nordisk Establishes First Hemostasis Research Center in the US

Center to focus on next generation hemostasis therapies

Princeton, N.J. (May 4, 2005) - Novo Nordisk, a world leader in hemostasis therapy, today announced plans to open a first-of-its-kind hemostasis research center in North Brunswick, NJ, an area recognized for high-technology and novel biomedical research. Scheduled to open in the third quarter of 2005, the 30,000 square foot facility represents a major expansion of Novo Nordisk's research in the area of hemostasis. .
The new center will focus primarily on discovering new pharmacological targets for hemostasis and related complications. Researchers will also conduct preclinical trials to support NovoSeven® Coagulation Factor VIIa (Recombinant) in new therapeutic areas to advance exploration of next generation hemostasis therapies.
By year's end, at least 25 full-time research positions will be created, with the goal of 60 positions in the next few years. Novo Nordisk will begin recruiting for researchers and biotechnology experts in hemostasis and critical care medicine. Novo Nordisk will also seek to develop collaborations with neighboring laboratories and clinical centers.
"Although Novo Nordisk's focus is historically in diabetes research and treatment, creating new therapies in critical bleeding is a very important area to further explore because available treatment is far from optimal," said Dr. Peter Kurtzhals, senior vice president and head of global discovery, Novo Nordisk. "The investment in the new research center underscores Novo Nordisk's commitment to meeting unmet medical needs in the area of hemostasis."
The facility has been designed with a unique modern architecture, including state of the art labs and offices surrounding a central "research square." The Scandinavian design, typical of Novo Nordisk, creates an open and innovative environment facilitating employee interaction and communication.
This project is the result of successful collaborative efforts among the State Government of New Jersey, the Healthcare Institute of New Jersey and Novo Nordisk. The facility is located in The Technology Centre of New Jersey, a high-tech research park in North Brunswick developed by the New Jersey Economic Development Authority (EDA). The state-of-the-art 50-acre site has been specifically designed around the needs of high-technology companies, especially those in the biosciences.
"New Jersey has a rich history of encouraging and supporting the growth of pharmaceutical companies," said EDA chief executive officer Caren S. Franzini. "Novo Nordisk is a great example of how the public and private sectors can work in partnership to promote the development of new drug therapies, strengthen our State's scientific community, and create high paying jobs."
Additional financial incentives provided by the EDA include a Business Employment Incentive Program grant totaling more than $3.3 million dollars, a significant participation in the financing of the lease agreement, and shared expenses for related site improvements.
"This investment is yet another example of how New Jersey is strengthening its position as a global leader in the life sciences," said state treasurer John E. McCormac. "New Jersey is the world's medicine chest because pharmaceutical companies are creating, marketing, and distributing drugs here. Novo Nordisk's investment illustrates how we're nurturing research and development - the key for long term success," McCormac said.